Yu H, Nicar M R, Shi R, Berkel H J, Nam R, Trachtenberg J, Diamandis E P
Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana 71104, USA
Urology. 2001 Mar;57(3):471-5. doi: 10.1016/s0090-4295(00)01003-7.
To determine changes of insulin-like growth factor I (IGF-I), IGF binding protein-2 (IGFBP-2), and IGFBP-3 levels in serial postoperative serum samples from prostate cancer patients with and without relapse and to evaluate the prognostic value of these molecules in the recurrence of prostate cancer.
From a group of patients with prostate cancer who had been followed for disease recurrence for almost 5 years after radical prostatectomy, we selected 38 patients (cases) who developed recurrent disease and 40 patients (controls) who were in remission. Of these patients, 70 had 4 and 8 had 3 serial postoperative serum samples collected. The median times for serum collection after surgery were 1.5 years for the first serial samples, 2.6 years for the second, 3.5 years for the third, and 4.5 years for the fourth. Serum levels of IGFBP-2, IGFBP-3, and IGF-I were measured, using commercial immunoassay kits.
The study showed lower serum levels of IGFBP-2 and IGFBP-3 in the cases than in controls(P <0.05) but no difference in IGF-I levels between the two groups (P = 0.277). In the sequential samples, IGFBP-2 levels increased over time in the controls (P = 0.014) but did not change in the cases (P = 0.528). There were no increasing or decreasing trends for IGF-I and IGFBP-3 in either case or control group(P >0.05).
The study suggests that IGFBP-2 may play a role in the progression of prostate cancer, but serum levels of IGFBP-2 as well as IGF-I and IGFBP-3 have no predictive values in the prognosis of prostate cancer.
测定前列腺癌患者术后复发和未复发系列血清样本中胰岛素样生长因子I（IGF-I）、IGF结合蛋白-2（IGFBP-2）和IGFBP-3水平的变化，并评估这些分子在前列腺癌复发中的预后价值。
从一组前列腺癌患者中选取，这些患者在根治性前列腺切除术后已随访疾病复发近5年，我们选择了38例复发疾病患者（病例组）和40例缓解患者（对照组）。在这些患者中，70例有4份术后系列血清样本，8例有3份术后系列血清样本。术后首次系列样本血清采集的中位时间为1.5年，第二次为2.6年，第三次为3.5年，第四次为4.5年。使用商业免疫分析试剂盒测量血清中IGFBP-2、IGFBP-3和IGF-I水平。
研究显示病例组血清IGFBP-2和IGFBP-3水平低于对照组（P<0.05），但两组IGF-I水平无差异（P = 0.277）。在连续样本中，对照组IGFBP-2水平随时间升高（P = 0.014），而病例组无变化（P = 0.528）。病例组和对照组中IGF-I和IGFBP-3均无升高或降低趋势（P>0.05）。
该研究表明IGFBP-2可能在前列腺癌进展中起作用，但IGFBP-2以及IGF-I和IGFBP-3的血清水平在前列腺癌预后中无预测价值。
